Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorThe Affiliated Hospital of Qingdao University
About this trial
This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \[PCI\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET/MR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET/MR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure.
Disqualifiers
Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions.
Trial population
clinically diagnosed with first-episode AMI and undergoing interventional therapy
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
20 Participants
are grouped into 1 trial groupGroup A: clinically diagnosed with first-episode AMI and undergoing interventional therapy
Trial outcomes
Primary outcomes
1
The myocardial uptake of 18F-Pentixafor was quantified using SUVmax and SUVmean values derived from PET imaging.
Time frame
At baseline (within 1 week of enrollment)2
Left ventricular ejection fraction (LVEF) assessed by cardiac MRI to evaluate left ventricular function
Time frame
At baseline (within 1 week of enrollment)3
Infarct Characterization
Late gadolinium enhancement (LGE) images were used to calculate infarct size (IS).
Time frame
At baseline (within 1 week of enrollment)Secondary outcomes
1
Myocardial T1 Values and Extracellular Volume (ECV)
Myocardial T1 values within the LGE territory were measured to yield native T1 and post-contrast T1 values. ECV was calculated using the native and post-contrast myocardial T1 values, blood pool T1 values, and the hematocrit (HCT).
Time frame
At baseline (within 1 week of enrollment)2
Myocardial T2 values
Myocardial T2 values were quantified using T2 mapping images to assess myocardial edema.
Time frame
At baseline (within 1 week of enrollment)3
Myocardial Strain Analysis
Feature-tracking analysis (CMR-FT module, CVI42) was performed offline on cine sequences. LV endocardial and epicardial contours were automatically tracked at end-diastole and end-systole, followed by manual adjustments as necessary. Global and segmental myocardial strain values were derived.
Time frame
At baseline (within 1 week of enrollment)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov